This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
by Zacks Equity Research
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Regeneron (REGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed the most recent trading day at $581.01, moving +0.56% from the previous trading session.
Zacks.com featured highlights include: Dollar General, Canon, Tyler Technologies, Regeneron Pharmaceuticals and Fanhua
by Zacks Equity Research
Zacks.com featured highlights include: Dollar General, Canon, Tyler Technologies, Regeneron Pharmaceuticals and Fanhua
REGN or INCY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
REGN vs. INCY: Which Stock Is the Better Value Option?
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars
by Zacks Equity Research
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Zacks.com featured highlights include: Dollar General, Canon, Tyler Technologies, Regeneron Pharmaceuticals and Fanhua
by Zacks Equity Research
Zacks.com featured highlights include: Dollar General, Canon, Tyler Technologies, Regeneron Pharmaceuticals and Fanhua
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $583.72, marking a -0.6% move from the previous day.
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers
by Zacks Equity Research
Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX
by Zacks Equity Research
The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Buy These 5 Low-Beta Stocks to Beat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. DG, CAJ, TYL, REGN & FANH are the frontrunners.
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
by Zacks Equity Research
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
Regeneron (REGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $589.32 in the latest trading session, marking a +1.42% move from the prior day.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
by Zacks Equity Research
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
by Zacks Equity Research
The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now
by Zacks Equity Research
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.
Top Analyst Reports for Oracle, Lockheed Martin & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Lockheed Martin (LMT), and Boston Scientific (BSX).
Regeneron (REGN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).